ARTEFICIAL INTELLIGENCE-BASED CLINICAL DECISION SUPPORT TOOL FOR PERSONALIZED HCC RISK STRATIFICATION
.
PROJECT DESCRIPTION
Hepatocellular carcinoma (HCC) is the most common malignant liver disease with an increasing incidence in the EU and a strong gender-specific prevalence. It is the second most common cause of cancer-related death in men and the ninth most common in women. NASH is the fastest growing cause of HCC-related deaths, followed by alcohol, due to rising obesity rates. Despite advances in the understanding of the carcinogenic process in cirrhosis, there is no established method for early detection of premalignant lesions. HCC is often only diagnosed in advanced stages, which limits survival rates.
The planned study uses multidimensional data and AI to analyze the development of liver cancer from unclassified nodules. The TiPredict system is expected to enable early detection and prevention of HCC, comparable to colonoscopy screenings.
The results can revolutionize the diagnosis and treatment of cirrhosis, promote personalized therapies and help patients through earlier and more precise treatment.
.
Project Leader Dr. Höhme, IZBI
Duration 01.06.2024 – 31.05.2027
Extern Project Website https://www.hoehme.com/
Funding third-party funding